CLDN6 and congenital rubella syndrome: In humans, the BNT14201 Phase I/II trial of an mRNA-LNP - encoded CLDN6 × CD3 bispecific reported mild cytokine elevations in 22% of patients, with only one case of grade 3 CRS among 65 patients - an acceptable safety profile compared to protein-based bsAbs (154)(Stadler et al., 2024; OncoDaily Jun 1 2025).